Abstract: Compositions and methods for hydrogen production are disclosed.

Abstract: The disclosure discloses a preparation of type I collagen-like fibers and a method for regulating and controlling the periodic length of fiber stripes thereof, belonging to the technical field of genetic engineering. The disclosure produces a three-segment chimeric collagen P-CL-P pattern by inserting a continuous Gly-Xaa-Yaa triplet collagen sequence in the middle based on the N- and C-terminal (GPP)n sequences. The self-assembly is driven by the interaction between the N- and C-terminal (GPP)n triple helixes to form banded fibers with periodic bright and dark stripes. According to the method of the disclosure, a fiber from a clean source, which can self-assemble to form periodic bright and dark stripes can be prepared, the structure of which is similar to type I collagen, the preparation process is simple, the collagen fiber with low cost can be produced on a large scale, and the method has broad application prospects in the field of biological materials.

Abstract: The disclosure discloses a preparation of type I collagen-like fibers and a method for regulating and controlling the periodic length of fiber stripes thereof, belonging to the technical field of genetic engineering. The disclosure produces a three-segment chimeric collagen P-CL-P pattern by inserting a continuous Gly-Xaa-Yaa triplet collagen sequence in the middle based on the N- and C-terminal (GPP)n sequences. The self-assembly is driven by the interaction between the N- and C-terminal (GPP)n triple helixes to form banded fibers with periodic bright and dark stripes. According to the method of the disclosure, a fiber from a clean source, which can self-assemble to form periodic bright and dark stripes can be prepared, the structure of which is similar to type I collagen, the preparation process is simple, the collagen fiber with low cost can be produced on a large scale, and the method has broad application prospects in the field of biological materials.

Abstract: Various embodiments of the present disclosure provide for an exemplary method that includes: obtaining a modified compound having an improved dissolution in a solution than an original compound; where the modified structure is determined based at least in part on: i) sampling a plurality of molecular conformations of at least one of: 1) the original compound or 2) a plurality of candidate structures; where each candidate structure differs from the original compound in a conformational change, a structural change, or both; comparing, by a processor, average zeta potentials of the plurality of candidate structures among each other and to an average zeta potential of the original compound; and determining, by the processor, based on the comparing, a desired candidate structure, expected to have a higher solubility in the solution; and adapting a desired compound having the at least one desired candidate structure to the solution.

Abstract: This invention relates generally to a field of rational drug design. In particular, the present invention relates to a 19 F NMR assay for screening inhibitors of specific protein-target interactions, preferably those that inhibit influenza A NS 1 protein and can be useful in treating influenza A viral infections. The invention also relates to agents, compositions, and methods for treating influenza A viral infections.